$1.21
1.63% day before yesterday
Nasdaq, Dec 27, 10:01 pm CET
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Editas Medicine, Inc. Stock price

$1.21
-0.99 45.00% 1M
-3.53 74.47% 6M
-8.92 88.06% YTD
-9.17 88.34% 1Y
-26.94 95.70% 3Y
-29.25 96.03% 5Y
-16.99 93.35% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.02 1.63%
ISIN
US28106W1036
Symbol
EDIT
Sector
Industry

Key metrics

Market capitalization $99.88m
Enterprise Value $-126.72m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.66
EV/Sales (TTM) EV/Sales -2.05
P/S ratio (TTM) P/S ratio 1.62
P/B ratio (TTM) P/B ratio 0.57
Revenue growth (TTM) Revenue growth 150.95%
Revenue (TTM) Revenue $61.76m
EBIT (operating result TTM) EBIT $-228.52m
Free Cash Flow (TTM) Free Cash Flow $-191.36m
Cash position $265.09m
EPS (TTM) EPS $-2.56
P/E forward negative
P/S forward 2.65
EV/Sales forward negative
Short interest 24.64%
Show more

Is Editas Medicine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Editas Medicine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Editas Medicine, Inc. forecast:

5x Buy
26%
12x Hold
63%
2x Sell
11%

Analyst Opinions

19 Analysts have issued a Editas Medicine, Inc. forecast:

Buy
26%
Hold
63%
Sell
11%

Financial data from Editas Medicine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
62 62
151% 151%
100%
- Direct Costs 5.89 5.89
5% 5%
10%
56 56
203% 203%
90%
- Selling and Administrative Expenses 64 64
4% 4%
104%
- Research and Development Expense 214 214
39% 39%
347%
-223 -223
10% 10%
-360%
- Depreciation and Amortization 5.89 5.89
5% 5%
10%
EBIT (Operating Income) EBIT -229 -229
10% 10%
-370%
Net Profit -211 -211
8% 8%
-341%

In millions USD.

Don't miss a Thing! We will send you all news about Editas Medicine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Editas Medicine, Inc. Stock News

Negative
Reuters
16 days ago
Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies that edit genes within the body.
Neutral
GlobeNewsWire
16 days ago
CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced a critical pivot to optimize its cost structure, extend its cash runway into Q2 2027, and position the Company to accelerate its intent to achieve in vivo human proof of concept in approximately two years.
More Editas Medicine, Inc. News

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Head office United States
CEO Gilmore O’Neill
Employees 265
Founded 2013
Website www.editasmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today